Grifols (GRF) AI Stock Analysis

• Market Cap: €5.57B
• Dividend Yield: 1.37%
• Average Volume (3M): 1.09M
• Price to Earnings (P/E): 18.7
• Beta (1Y): 0.87
• Revenue Growth: 7.31%
• EPS Growth: 158.58%
• Country: ES
• Employees: 23,833
• Sector: General
• Sector Strength: N/A
• Industry: Drug Manufacturers - General
• EPS (TTM): 0.14
• Shares Outstanding: 426,129,800
• 10 Day Avg. Volume: 1,216,950
• 30 Day Avg. Volume: 1,090,725
• PEG Ratio: 0.12
• Price to Book (P/B): 1.40
• Price to Sales (P/S): 0.98
• P/FCF Ratio: 9.41
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: €11.00
• Price Target Upside: 21.55% Upside
• Rating Consensus: Hold
• Number of Analyst Covering: 1
• EPS Forecast (FY): 0.87
• Revenue Forecast (FY): €7.78B

• Rating: 53 Neutral
• Price Target: €9.00 ▼(-0.55% Downside)
• Action: Reiterated Date: 03/06/26
• Date: Action: Reiterated 03/06/26

The score is primarily constrained by balance-sheet risk (high leverage and limited debt coverage) despite improving revenue, margins, and cash generation. Weak technical signals (below major moving averages with negative MACD) further weigh on the outlook, while a reasonable P/E and modest dividend provide only partial support.

Positive Factors

Diversified business model

Grifols' vertical model — plasma collection, fractionation and commercial distribution combined with Diagnostics' instrument-plus-reagent annuity — creates durable, recurring revenue streams. This integration secures supply, captures value across the chain and builds structural revenue resilience versus pure-play peers.

Negative Factors

Elevated leverage

High absolute debt and a debt-to-equity ratio near 1.8x materially reduce financial flexibility. Interest and principal obligations constrain capital allocation, limit ability to invest aggressively or pursue M&A, and raise refinancing vulnerability if cash generation weakens or rates rise over the medium term.

Grifols Business Overview & Revenue Model

Company Description

Grifols, S.A. engages in the procurement, manufacture, preparation, and sale of therapeutic products, primarily hemoderivatives. The company operates through Bioscience, Hospital, Diagnostic, Bio Supplies, and Others divisions. The Bioscience divi...

Read more

Grifols, S.A. engages in the procurement, manufacture, preparation, and sale of therapeutic products, primarily hemoderivatives. The company operates through Bioscience, Hospital, Diagnostic, Bio Supplies, and Others divisions. The Bioscience divi...

How the Company Makes Money

Grifols primarily makes money by collecting human plasma through its network of plasma donation centers and converting that plasma into plasma-derived medicines that are sold to hospitals, pharmacies, and healthcare systems. A key revenue stream c...

Read more

Grifols primarily makes money by collecting human plasma through its network of plasma donation centers and converting that plasma into plasma-derived medicines that are sold to hospitals, pharmacies, and healthcare systems. A key revenue stream c...

Grifols Financial Statement Overview

Breakdown	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	7.52B	7.21B	6.59B	6.06B	4.93B
Gross Profit	2.86B	2.85B	2.49B	2.23B	1.96B
EBITDA	1.25B	1.61B	1.18B	1.21B	944.03M
Net Income	401.89M	156.92M	59.31M	208.28M	265.33M
Balance Sheet
Total Assets	19.71B	21.41B	21.44B	21.53B	19.23B
Cash, Cash Equivalents and Short-Term Investments	825.49M	1.00B	645.72M	591.24M	2.68B
Total Debt	8.74B	10.09B	10.12B	9.75B	9.32B
Total Liabilities	12.11B	12.80B	13.47B	13.08B	11.09B
Stockholders Equity	5.27B	5.88B	5.83B	6.13B	6.10B
Cash Flow
Free Cash Flow	782.00M	669.63M	-87.14M	-386.43M	281.89M
Operating Cash Flow	1.05B	902.17M	208.28M	-10.87M	596.98M
Investing Cash Flow	-579.00M	886.67M	-397.64M	-1.98B	-29.39M
Financing Cash Flow	-529.00M	-1.36B	186.04M	-173.49M	1.47B

Grifols Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 9.05
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ES:GRF, the sentiment is Negative. The current price of 9.05 is above the 20-day moving average (MA) of 9.02, below the 50-day MA of 10.05, and below the 200-day MA of 11.14, indicating a bearish trend. The MACD of -0.27 indicates Negative momentum. The RSI at 41.23 is Neutral, neither overbought nor oversold. The STOCH value of 47.05 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for ES:GRF.

Grifols Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
ROVI	73 Outperform	€4.21B	23.13	23.03%	1.50%	-9.39%	-25.92%
PHM	71 Outperform	€1.65B	17.19	35.36%	1.04%	7.35%	5375.64%
ALM	59 Neutral	€2.79B	35.12	3.96%	1.22%	13.32%	―
Sector *	55 Neutral	$6.65B	3.83	-15.92%	6.20%	10.91%	7.18%
GRF	53 Neutral	€5.57B	18.75	7.56%	1.37%	7.31%	158.58%
FAE	51 Neutral	€1.53B	20.17	18.13%	3.51%	11.04%	8.29%
RJF	46 Neutral	€209.08M	41.66	2.03%	1.91%	-1.19%	-54.66%